Updated:
Predictive Oncology Inc.
Predictive Oncology Inc. uses AI and the world's largest private tumor biobank to predict drug responses for biopharma partners.
Predictive Oncology Inc.
Predictive Oncology Inc. is headquartered in Pittsburgh, Pennsylvania, and operates a proprietary platform that integrates active machine learning with a biobank of over 150,000 tumor samples (per the firm, 2026). The company collaborates with biopharma partners to improve drug discovery and clinical trial outcomes, leveraging patient-derived dissociated tumor cells to model drug efficacy. The firm focuses on three core activities: AI-driven drug-response prediction, 3D tumor model development, and clinical testing services. Its platform screens compounds against a diverse collection of tumor samples to identify the most promising drug-tumor type combinations. Predictive Oncology serves the US biopharma market and has presented research at SLAS Europe 2026 on integrated imaging and viability analysis using its biobank (per the firm, 2026). The company also publishes white papers on drug repurposing for cancers of the breast, colon, and ovary. The company's biobank, which it describes as the world's largest privately held collection of tumor samples, is the key differentiator for its prediction engine. The firm has not disclosed total team size, AUM, or funding rounds, and does not provide public information on investment backers or ownership structure. It maintains a single headquarters in Pittsburgh. Predictive Oncology's structural differentiator is its combination of a large, proprietary biological asset (tumor biobank) with an active machine learning system, which it claims enables high-confidence drug-response predictions before clinical trials. This model reduces reliance on traditional animal testing and positions the firm as a service provider to biopharma rather than a drug developer itself.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Pittsburgh
Corporate office
91 43rd Street Suite 110, Pittsburgh, PA 15201, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Predictive Oncology?
Predictive Oncology Inc. is a publicly traded company (NASDAQ: POAI) with a board of directors and executive management team. The firm does not disclose individual investment decision-makers publicly, and no named principals were found in available sources.
How does Predictive Oncology source proprietary deal flow?
Predictive Oncology sources proprietary deal flow through its offerings in drug discovery and clinical testing services. The company's biobank of over 150,000 tumor samples and its AI platform attract biopharma partners seeking drug-response testing and prediction, generating revenue from service contracts rather than venture-style investments.
Is Predictive Oncology structured as a family office or does it operate more like a venture firm?
Predictive Oncology Inc. is a publicly traded corporation (NASDAQ: POAI) that operates as a drug discovery and testing services firm. It is not structured as a family office or venture firm; it generates revenue by providing predictive modeling and laboratory services to biopharmaceutical partners.
Does Predictive Oncology participate in fund commitments or only direct deals?
Predictive Oncology does not participate in fund commitments. It is a service provider that uses its AI platform and tumor biobank to assist biopharma partners in drug development. The firm's revenue comes from service contracts, not from investing in external funds or making direct investments.
What investment stages does Predictive Oncology typically target?
Predictive Oncology is not an investment firm; it is a drug discovery and testing company. It targets the pre-clinical and early clinical development stages of the pharmaceutical pipeline, helping partners select drug candidates and predict efficacy before expensive clinical trials.
Which sectors does Predictive Oncology explicitly avoid?
Predictive Oncology explicitly focuses on oncology and drug discovery. The firm does not target sectors outside of cancer therapeutics and drug development, including no exposure to finance, real estate, or technology unrelated to healthcare.
Does Predictive Oncology maintain philanthropic structures?
There is no public information indicating that Predictive Oncology Inc. maintains philanthropic foundations or charitable arms. The firm appears to operate as a for-profit, publicly traded entity solely focused on its drug discovery and testing business.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: